Evidence map›Paper›PMID 36434378›Full record

ArticleJournal of community genetics2023

Cost-effectiveness of a gene sequencing test for Alzheimer's disease in Ontario.

Nicolas Iragorri, Danielle Toccalino, Sujata Mishra, Brian Cf Chan, Allison A Dilliott, John F Robinson, Robert A Hegele, Rebecca Hancock-Howard, ONDRI Investigators

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of community genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nicolas IragorriInstitute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. nicolas.iragorri@mail.utoronto.ca.
Danielle ToccalinoInstitute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Sujata MishraInstitute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Brian Cf ChanKITE - Toronto Rehabilitation Institute, Institute for Health Policy, Management and Evaluation, University Health Network, University of Toronto, Toronto, ON, Canada.
Allison A DilliottDepartment of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
John F RobinsonRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Robert A HegeleRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Rebecca Hancock-HowardInstitute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
ONDRI Investigators
University of Toronto · CAWestern University · CAMontreal Neurological Institute and Hospital · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's f disease (AD) affects approximately 250,000 Ontarians, a number that is expected to double by 2040. The Ontario Neurodegenerative Disease Research Initiative has developed an in-province genetic test (ONDRISeq), which currently runs in Ontario in an experimental capacity. The aim of this study is to estimate the costs and health outcomes associated with ONDRISeq to diagnose AD relative to out-of-country (OOC) testing (status quo). A cost-utility analysis was developed for a hypothetical cohort of 65-year-olds at risk of AD in Ontario over a 25-year time horizon. Costs and health outcomes (quality-adjusted life years (QALYs)) were assessed from a healthcare payer perspective. Cost-effectiveness was assessed with a $50,000 cost-effectiveness threshold. Probabilistic sensitivity analyses were conducted to evaluate parameter uncertainty. ONDRISeq saved $54 per patient relative to OOC testing and led to a small QALY gain in the base case (0.0014 per patient). Results were most sensitive to testing costs, uptake rates, and treatment efficacy. ONDRISeq represented better value for money relative to OOC testing throughout 75% of 10,000 probabilistic iterations. Using ONDRISeq is expected to provide health system cost savings. Switching to ONDRISeq for AD genetic testing in Ontario would be dependent on the ability to accommodate the expected testing volumes.

Indexed as

Alzheimer’sCost-effectivenessMarkov modelNeurogenetics

Identifiers

PMID36434378
PMCPMC10104984
OpenAlexW4309955067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.